AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00309842
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW \> 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
Trial: NCT05399212
Drug: FPT-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPT-20 should be used regularly, the daily maintenance dose is 1 tablet once a day(\>6 to 12 months) until the therapeutic purpose is achieved.
Trial: NCT02371187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
Trial: NCT03268278
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1,8 ml
Trial: NCT03268278
Drug: lidocaine, epinephrine (Local anesthetic)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine 1:100,000 epinephrine
Trial: NCT04070846
Drug: [14C] LC350189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon-14 labelded LC350189
Trial: NCT03499743
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib 200mg (Celebrex® 200, Pfizer, USA) in addition to a placebo similar to hyoscine butyl bromide
Trial: NCT03499743
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a placebo similar to hyoscine butyl bromide in addition to a placebo similar to Celecoxib.
Trial: NCT01516476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 12 weeks
Trial: NCT01516476
Drug: RO6807952
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses for 12 weeks
Trial: NCT01175746
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1-0.5 ugkg/min during hypotensive anesthesia
Trial: NCT04003402
Drug: ASP8062
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04003402
Drug: ASP8062 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04003402
Drug: Alcohol Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02586194
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT03168984
Drug: UCB0942
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Pharmaceutical form: Film-coated tablet~* Route of administration: Oral use
Trial: NCT03148002
Drug: PEG Bowel Protocol (PEG/lactulose)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osmotic Laxatives.
Trial: NCT02048007
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Biannual mass oral azithromycin to children
Trial: NCT02048007
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biannual mass oral placebo to children
Trial: NCT00999557
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Applied topically
Trial: NCT00863304
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 1000 mg daily for 16 weeks
Trial: NCT03921567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will be given opioids during surgery, and opioids and nonsteroid antiinflammatory agents will be given 48 hours after surgery.
Trial: NCT04687930
Drug: intra-articular steroid injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinilone injection into the knee joint under ultrasound guidance.
Trial: NCT03685149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
Trial: NCT01370044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 minutes administration of oxygen
Trial: NCT03864328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Placebo administered TID via eFlow nebulizer
Trial: NCT03941561
Drug: S-1 for 9 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 for 9 months after D2 resection
Trial: NCT03941561
Drug: S-1 for 1 year
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 for 1 year after D2 resection
Trial: NCT00167245
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills
Trial: NCT02172157
Drug: BI 1744 CL i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01767987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
Trial: NCT02835105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral dose of placebo for surotomycin in hard gelatin capsules
Trial: NCT04148209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo
Trial: NCT02014376
Drug: SD-101 dermal cream (3%)
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-3.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 3% and other excipients.
Trial: NCT02014376
Drug: SD-101 Dermal Cream (6%)
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SD-101 is a white, crystalline powder that is formulated within an odorless, soft, white cream base. SD-101-6.0 cream contains allantoin, a diureide glyoxylic acid, at a concentration of 6% and other excipients.
Trial: NCT00517790
Drug: ABT-869 .25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
Trial: NCT00517790
Drug: ABT-869 0.10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
Trial: NCT01172392
Drug: Nucleotidic or Nucleosidic Treatment
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analog treatment according to investigators practice
Trial: NCT01331655
Drug: EE20/DRSP (BAY86-5300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
Trial: NCT01331655
Drug: EE20/DRSP/L-5-MTHF (BAY98-7071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
Trial: NCT01331655
Drug: EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
Trial: NCT00105066
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet once a day for one month, then twice a day for 3 months
Trial: NCT00159445
Drug: gemcitabine, capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03321942
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
Trial: NCT03321942
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment were used to treat patients with chronic renal failure.
Trial: NCT00741377
Drug: BHQ880
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00741377
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00706173
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 10-20 mg PO daily for 4 weeks.
Trial: NCT00706173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10-20 mg PO daily for 4 weeks.
Trial: NCT00619866
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet administered orally
Trial: NCT00240266
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02129621
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
Trial: NCT00471393
Drug: 1.5% diclofenac in 45.5% DMSO (topical treatment)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00471393
Drug: 45.5% DMSO (topical placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02965274
Drug: Torrent's Fluoxetine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02965274
Drug: Warner Chilcott LLC's Sarafem Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04102566
Drug: Ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We'll be adding ibuprofen while trying to limit oxycodone use while hospitalized. Patients will not be discharged with a narcotic.
Trial: NCT03070665
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
Trial: NCT03436849
Drug: ESN364
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESN364 will be administered orally.
Trial: NCT03436849
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally.
Trial: NCT00916747
Drug: Lonafarnib, Zoledronic Acid, and Pravastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.~Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.~Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily.
Trial: NCT01136850
Drug: azithromycin, sulphadoxine pyrimethamine, LLIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).~Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation.
Trial: NCT01342315
Drug: 33525
RxNorm normalized name: POUCH,CLOSED,KARAYA SEAL H#3325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing
Trial: NCT01342315
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing
Trial: NCT00075582
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00867152
Drug: GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
Trial: NCT01950520
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 200mg, oral, by mouth (Cohort 2 only)
Trial: NCT01950520
Drug: Placebo Cohort 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral, by mouth (Cohort 1 only)
Trial: NCT01950520
Drug: Placebo Cohort 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral, by mouth (Cohort 2 only)
Trial: NCT03344705
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days
Trial: NCT04614337
Drug: LUM-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally once daily
Trial: NCT04614337
Drug: rhGH Norditropin® pen (34 µg/kg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) once daily.
Trial: NCT01064726
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg oral
Trial: NCT01064726
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02442960
Drug: Herbal treatment (SA100)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This treatment has been used extensively in traditional medicine practices for hundreds of years.
Trial: NCT01081756
Drug: r-hCG
RxNorm normalized name: pantolactone, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)
Trial: NCT00694057
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules BID
Trial: NCT01044719
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin 7mg/kg/day OD IV
Trial: NCT03463187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT00301860
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01606241
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT04573504
Drug: Augmentin/Flagyl or Augmentin/Clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who suffer a severe vaginal laceration at Prentice Women's Hospital will be randomized to receive 5-days of oral antibiotics or placebo pills after getting a standard one-time dose of IV antibiotics at the time of repair.
Trial: NCT04573504
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01202084
Drug: Foraseq®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03756961
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The control group receives general anesthesia with Remifentanil as the routine opioid drug during general anesthesia.
Trial: NCT02140255
Drug: Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
RxNorm normalized name: Non-nucleoside reverse transcriptase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chosen by the site investigator and dosed according to World Health Organization (WHO) or individual country or local standard guidelines.
Trial: NCT02924727
Drug: LCZ696 (sacubitril/valsartan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
Trial: NCT03664544
Drug: MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg MCI-186 will be administered intravenously over 60 minutes.
Trial: NCT00835367
Drug: Lotrel® 10 mg-20 mg capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 10-20 mg
Trial: NCT00835172
Drug: AMARYL® 4 mg Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x 4 mg, single-dose non-fasting
Trial: NCT03424733
Drug: Tylenol Pill
RxNorm normalized name: Tylenol Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take two 325 milligram Tylenol tablets 1 hour prior to each Plegridy injection, irregardless of dosage.
Trial: NCT03462121
Drug: RPh201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPh201 is a well-defined extract from a botanical source
Trial: NCT01524744
Drug: Adcortyl
RxNorm normalized name: Adcortyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: triamcinolone acetonide 0.1% in orabase
Trial: NCT01556334
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 1g po
Trial: NCT01556334
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin IV then PO
Trial: NCT00977444
Drug: kondrium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraarticular injections once month
Trial: NCT00977444
Drug: kondrium f
RxNorm normalized name: Stomodine F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intraarticular injections once month
Trial: NCT04218981
Drug: Antipsychotic drugs
RxNorm normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choose one of these antipsychotics (olanzapine, risperidone; amisulpride) for schizophrenia group
Trial: NCT04218981
Drug: Mood stabilizer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choose lithium or valproate for bipolar disorder group
Trial: NCT01137084
Drug: a steroid-free immunosuppression protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
Trial: NCT02140255
Drug: VRC01
RxNorm normalized name: VRC01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg administered subcutaneously.
Trial: NCT02140255
Drug: VRC07-523LS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg administered subcutaneously.
Trial: NCT00864357
Drug: Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
Trial: NCT00864357
Drug: COMBONOX® tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
Trial: NCT00830531
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
Trial: NCT00685295
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl rapid dissolving tablet 100mcg
Trial: NCT03440411
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg every other day as oral administration (PO) on days 1-28
Trial: NCT03446690
Drug: MI Varnish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MI Varnish with RECALDENT™ (CPP-ACP) enhances enamel acid resistance and boosts salivary fluoride levels. This product remains on the teeth longer than other fluoride varnishes and contains high levels of fluoride and calcium released in the oral cavity. The difference is in the RECALDENT™ (CPP-ACP), which makes MI Varnish a natural and unique choice for your patients. Casein phosphopeptides (CPP) naturally occurs in milk casein; Amorphous Calcium Phosphate (ACP), which is found in the RECALDENT™, is also the source of calcium and phosphate. In the oral cavity, CPP binds to oral surfaces such as teeth, dentin, oral mucosa and biofilm. Calcium and phosphate ions are the building blocks for healthy teeth and MI Varnish delivers bioavailable calcium and phosphate ions into the saliva.
Trial: NCT01882816
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.
Trial: NCT01900184
Drug: QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01900184
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contains magnesium stearate, silica dental type, anhydrous lactose